 <h1>Accolate Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>zafirlukast</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about zafirlukast. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Accolate.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to zafirlukast: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, zafirlukast (the active ingredient contained in Accolate) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking zafirlukast:</p><p>
<i>Less common</i>
</p><ul>
<li>Cough or hoarseness</li>
<li>fever or chills</li>
<li>lower back or side pain</li>
<li>pain</li>
<li>painful or difficult urination</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>clay-colored stools</li>
<li>dark urine</li>
<li>diarrhea</li>
<li>dizziness</li>
<li>headache</li>
<li>itching</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>rash</li>
<li>unpleasant breath odor</li>
<li>unusual tiredness or weakness</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Attack, assault, or force</li>
<li>attempts at killing oneself</li>
<li>discouragement</li>
<li>dry mouth</li>
<li>fear or nervousness</li>
<li>feeling sad or empty</li>
<li>fever with or without chills</li>
<li>general feeling of tiredness or weakness</li>
<li>hyperventilation</li>
<li>irregular heartbeats</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>loss of interest or pleasure</li>
<li>restlessness</li>
<li>seeing, hearing, or feeling things that are not there</li>
<li>shakiness in the legs, arms, hands, or feet</li>
<li>shortness of breath</li>
<li>sleeplessness</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>tiredness</li>
<li>trembling or shaking of the hands or feet</li>
<li>trouble with concentrating</li>
<li>trouble with sleeping</li>
<li>unable to sleep</li>
<li>unusual bleeding or bruising</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of zafirlukast may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>back pain</li>
<li>belching</li>
<li>difficulty with moving</li>
<li>heartburn</li>
<li>indigestion</li>
<li>joint pain</li>
<li>lack or loss of strength</li>
<li>muscle aching or cramping</li>
<li>muscle pains or stiffness</li>
<li>stomach discomfort or upset</li>
<li>swollen joints</li>
<li>vomiting</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Hives or welts</li>
<li>redness of the skin</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to zafirlukast: oral tablet</i></p><h3>General</h3><p>The most commons adverse effects may be associated with headache or gastrointestinal disturbances.  These symptoms are usually mild.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 12.9%)</p>
<p><b>Common</b> (1% to 10%): Dizziness (1.6%)</p>
<p><b>Frequency not reported</b>: Neuropathy, neuropsychiatric events<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea (up to 3.1%), diarrhea (up to 2.8%), abdominal pain (up to 2.8%), vomiting (up to 1.5%), dyspepsia (1.3%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p>In most of the postmarketing reports, the patient's symptoms abated and the liver enzymes returned to normal or near normal after stopping this drug.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): SGPT elevation (1.5%), AST (1.4%)</p>
<p><b>Rare</b> (less than 0.1%): Hyperbilirubinemia without other elevated liver function tests; fulminant hepatitis or progressed to hepatic failure, liver transplantation and death</p>
<p><b>Postmarketing reports</b>: Symptomatic hepatitis (with or without hyperbilirubinemia) without other attributable cause; hepatic dysfunction<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia (1.6%), back pain (1.5%)</p>
<p><b>Frequency not reported</b>: Arthralgia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Generalized pain (1.9%), asthenia (up to 1.8%), accidental injury (1.6%), fever (1.4%)</p>
<p><b>Rare</b> (less than 0.1%): Increased theophylline levels with or without clinical signs or symptoms of theophylline toxicity when this drug was added to an existing theophylline regime.</p>
<p><b>Frequency not reported</b>: Edema, malaise<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Respiratory tract infection (3.5%)<sup>[Ref]</sup></p><p>Infections were usually mild or moderate, predominantly affecting the respiratory tract and not necessitating withdrawal from the therapy.</p>
<p>In clinical trials, an increased proportion of patients over the age of 55 years reported these infections.  Infections occurred equally in both sexes and were associated with coadministration of inhaled corticosteroids.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Rare</b> (less than 0.1%): Bleeding disorders including menorrhagia, thrombocytopenia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Rare</b> (less than 0.1%): Alopecia</p>
<p><b>Frequency not reported</b>: Bruising, pruritus<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (0.01% to 0.1%): Granulomatosis</p>
<p><b>Very rare</b> (less than 0.01%): Agranulocytosis<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Systemic eosinophilia may also involve various body systems including vasculitic rash, worsening pulmonary symptoms, cardiac complications or neuropathy.<sup>[Ref]</sup></p><p><b>Rare</b> (less than 0.1%): Systemic eosinophilia, eosinophilic pneumonia, or clinical features of vasculitis consistent with Churg-Strauss syndrome<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Urticaria, angioedema, rashes (with or without blistering)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Insomnia, depression<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Smith LJ, Geller S, Ebright L, Glass M, Thyrum PT "Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219." Am Rev Respir Dis 141 (1990): 988-92</p><p id="ref_5">5. Spector SL "Leukotriene inhibitors and antagonists in asthma." Ann Allergy Asthma Immunol 75 (1995): 463-70,473-4</p><p id="ref_6">6. Findlay SR, Barden JM, Easley CB, Glass M "Effect of the oral leukotriene antagonist, ICI 204,219, on antigen- induced bronchoconstriction in subjects with asthma." J Allergy Clin Immunol 89 (1992): 1040-5</p><p id="ref_7">7. Spector SL, Smith LJ, Glass M "Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group." Am J Respir Crit Care Med 150 (1994): 618-23</p><p id="ref_8">8. Kelloway JS "Zafirlukast: the first leukotriente-receptor antagonist approved for the treatment of asthma." Ann Pharmacother 31 (1997): 1012-21</p><p id="ref_9">9. Torres M,  Reddy KR "Severe liver injury." Ann Intern Med 135 (2001): 550</p><p id="ref_10">10. Danese S,  De Vitis I,  Gasbarrini A "Severe Liver Injury Associated with Zafirlukast." Ann Intern Med 135 (2001): 930</p><p id="ref_11">11. Wechsler ME, Drazen JM "Zafirlukast and Churg-Strauss syndrome." Chest 116 (1999): 266-7</p><p id="ref_12">12. Wechsler ME, Garpestad E, Rlier SR, et al. "Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast." JAMA 279 (1998): 455-7</p><p id="ref_13">13. Wechsler ME, Drazen JM "Zafirlukast and Churg-Strauss syndrome - Reply." JAMA 279 (1998): 1950</p><p id="ref_14">14. Finkel TH, Hunter DJ, Paisley JE, Finkel RS, Larsen GL "Drug-induced lupus in a child after treatment with zafirlukast (Accolate)." J Allerg Clin Immunol 103 (1999): 533-4</p><p id="ref_15">15. Knoell DL, Lucas J, Allen JN "Churg-Strauss syndrome associated with zafirlukast." Chest 114 (1998): 332-4</p><p id="ref_16">16. Green RL, Vayonis AG "Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment." Lancet 353 (1999): 725-6</p><p id="ref_17">17. Wechsler M, Drazen JM "Churg-Strauss syndome." Lancet 353 (1999): 1999</p><p id="ref_18">18. Honsinger RW "Zafirlukast and Churg-Strauss syndrome." JAMA 279 (1998): 1949</p><p id="ref_19">19. Katz RS, Papernik M "Zafirlukast and Churg-Strauss syndrome." JAMA 279 (1998): 1949</p><p id="ref_20">20. Churg J, Churg A "Zafirlukast and Churg-Strauss syndrome." JAMA 279 (1998): 1949-50</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Accolate (zafirlukast)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: leukotriene modifiers</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Accolate &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Asthma, Maintenance</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to zafirlukast: oral tablet</i></p><h3>General</h3><p>The most commons adverse effects may be associated with headache or gastrointestinal disturbances.  These symptoms are usually mild.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 12.9%)</p><p><b>Common</b> (1% to 10%): Dizziness (1.6%)</p><p><b>Frequency not reported</b>: Neuropathy, neuropsychiatric events<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea (up to 3.1%), diarrhea (up to 2.8%), abdominal pain (up to 2.8%), vomiting (up to 1.5%), dyspepsia (1.3%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p>In most of the postmarketing reports, the patient's symptoms abated and the liver enzymes returned to normal or near normal after stopping this drug.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): SGPT elevation (1.5%), AST (1.4%)</p><p><b>Rare</b> (less than 0.1%): Hyperbilirubinemia without other elevated liver function tests; fulminant hepatitis or progressed to hepatic failure, liver transplantation and death</p><p><b>Postmarketing reports</b>: Symptomatic hepatitis (with or without hyperbilirubinemia) without other attributable cause; hepatic dysfunction<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia (1.6%), back pain (1.5%)</p><p><b>Frequency not reported</b>: Arthralgia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Generalized pain (1.9%), asthenia (up to 1.8%), accidental injury (1.6%), fever (1.4%)</p><p><b>Rare</b> (less than 0.1%): Increased theophylline levels with or without clinical signs or symptoms of theophylline toxicity when this drug was added to an existing theophylline regime.</p><p><b>Frequency not reported</b>: Edema, malaise<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Respiratory tract infection (3.5%)<sup>[Ref]</sup></p><p>Infections were usually mild or moderate, predominantly affecting the respiratory tract and not necessitating withdrawal from the therapy.</p><p>In clinical trials, an increased proportion of patients over the age of 55 years reported these infections.  Infections occurred equally in both sexes and were associated with coadministration of inhaled corticosteroids.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Rare</b> (less than 0.1%): Bleeding disorders including menorrhagia, thrombocytopenia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Rare</b> (less than 0.1%): Alopecia</p><p><b>Frequency not reported</b>: Bruising, pruritus<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (0.01% to 0.1%): Granulomatosis</p><p><b>Very rare</b> (less than 0.01%): Agranulocytosis<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Systemic eosinophilia may also involve various body systems including vasculitic rash, worsening pulmonary symptoms, cardiac complications or neuropathy.<sup>[Ref]</sup></p><p><b>Rare</b> (less than 0.1%): Systemic eosinophilia, eosinophilic pneumonia, or clinical features of vasculitis consistent with Churg-Strauss syndrome<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Urticaria, angioedema, rashes (with or without blistering)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Insomnia, depression<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Smith LJ, Geller S, Ebright L, Glass M, Thyrum PT "Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219." Am Rev Respir Dis 141 (1990): 988-92</p><p id="ref_5">5. Spector SL "Leukotriene inhibitors and antagonists in asthma." Ann Allergy Asthma Immunol 75 (1995): 463-70,473-4</p><p id="ref_6">6. Findlay SR, Barden JM, Easley CB, Glass M "Effect of the oral leukotriene antagonist, ICI 204,219, on antigen- induced bronchoconstriction in subjects with asthma." J Allergy Clin Immunol 89 (1992): 1040-5</p><p id="ref_7">7. Spector SL, Smith LJ, Glass M "Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group." Am J Respir Crit Care Med 150 (1994): 618-23</p><p id="ref_8">8. Kelloway JS "Zafirlukast: the first leukotriente-receptor antagonist approved for the treatment of asthma." Ann Pharmacother 31 (1997): 1012-21</p><p id="ref_9">9. Torres M,  Reddy KR "Severe liver injury." Ann Intern Med 135 (2001): 550</p><p id="ref_10">10. Danese S,  De Vitis I,  Gasbarrini A "Severe Liver Injury Associated with Zafirlukast." Ann Intern Med 135 (2001): 930</p><p id="ref_11">11. Wechsler ME, Drazen JM "Zafirlukast and Churg-Strauss syndrome." Chest 116 (1999): 266-7</p><p id="ref_12">12. Wechsler ME, Garpestad E, Rlier SR, et al. "Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast." JAMA 279 (1998): 455-7</p><p id="ref_13">13. Wechsler ME, Drazen JM "Zafirlukast and Churg-Strauss syndrome - Reply." JAMA 279 (1998): 1950</p><p id="ref_14">14. Finkel TH, Hunter DJ, Paisley JE, Finkel RS, Larsen GL "Drug-induced lupus in a child after treatment with zafirlukast (Accolate)." J Allerg Clin Immunol 103 (1999): 533-4</p><p id="ref_15">15. Knoell DL, Lucas J, Allen JN "Churg-Strauss syndrome associated with zafirlukast." Chest 114 (1998): 332-4</p><p id="ref_16">16. Green RL, Vayonis AG "Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment." Lancet 353 (1999): 725-6</p><p id="ref_17">17. Wechsler M, Drazen JM "Churg-Strauss syndome." Lancet 353 (1999): 1999</p><p id="ref_18">18. Honsinger RW "Zafirlukast and Churg-Strauss syndrome." JAMA 279 (1998): 1949</p><p id="ref_19">19. Katz RS, Papernik M "Zafirlukast and Churg-Strauss syndrome." JAMA 279 (1998): 1949</p><p id="ref_20">20. Churg J, Churg A "Zafirlukast and Churg-Strauss syndrome." JAMA 279 (1998): 1949-50</p><h2>More about Accolate (zafirlukast)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>4 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: leukotriene modifiers</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Accolate &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Asthma, Maintenance</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>